Analysts expect Co-Diagnostics, Inc. to report a Q2 2026 consensus revenue of approximately $0.13 million and an EPS loss of $3.00, while the stock currently trades at $1.51 against a consensus analyst price target of $45.00. The primary focus for investors is the regulatory timeline and commercialization progress for the Co-Dx PCR Home and Point-of-Care platform, specifically seeking updates on the FDA 510(k) submission process.
This reporting period is critical as the company pivots from its legacy COVID-19 testing business, which has seen revenue collapse significantly from 2021 peaks. Management's ability to execute on the Saudi Arabian manufacturing joint venture and commercialize its new respiratory testing suite remains the central pillar for the company’s long-term recovery and cash preservation strategy.